Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

December 2025

A retrospective, multinational, cross-sectional survey of real-world outcomes for patients with axial spondyloarthritis receiving subcutaneous infliximab

BMC Rheumatology 2025;9:139 Doi: 10.1186/s41927-025-00594-9

Baraliakos X,

Lee YE,

Park S,

Lee YN,

In this real-world study, Baraliakos, et al. SC IFX demonstrated clinical effectiveness in both
r- and nr-axSpA, with consistent results across diverse patient characteristics. Both physicians and patients reported high satisfaction with no new safety concerns. Authors assessed the real-world outcomes of CT-P13 SC (SC IFX) as treatment for both r- and
nr-axSpA.

Keywords:

October 2025

Association between adalimumab dosing interval and uveitis recurrence in patients with ankylosing spondylitis

Biomedicines 2025;13:2089 Doi: 10.3390/biomedicines13092089

Lee Y,

Ahn SM,

Hong S,

Oh JS,

Lee CK,

Yoo B,

Kim YG

This study by Lee et al. is the first to evaluate the association between adalimumab dosing intervals and uveitis recurrence in patients with AS. Authors investigated whether extending the dosing interval of adalimumab influences the recurrence of uveitis in AS patients with a history of AU who are on adalimumab therapy.